Scholarlink

<p>Two novel series of indole-based scaffolds have been designed, synthesized, and screened for their anti-proliferative activities on the NCI-60 cell line panel. The novel structures of the indole-sulfonate and indole-aspirin mimic conjugates were designed as cyclin-dependent kinase 2 (CDK-2) inhibitors. The design approach depends on molecular hybridization between the indole scaffold and alkanesulfonates or with aspirin mimic analogs. The synthesized compounds were screened for their cytotoxic activity at a concentration of 10 <i>µ</i>M. Compound <b>8a</b> exhibited the most potent anticancer activity among the tested series and was further selected for the five-dose stage. At sub-micromolar doses, compound <b>8a</b> showed anti-cancer potency against a panel of 60 tumor cell lines, with log GI<sub>50</sub> values in the range from − 4.50 <i>µ</i>M to -6.45 µM. With log GI<sub>50</sub> values of -6.45, -6.42, -6.31, -5.96, and − 5.87 <i>µ</i>M, respectively, the most sensitive cell lines were leukemia (SR), melanoma (MDA-MB-435), CNS cancer (SNB-75), ovarian cancer (OVCAR-3), and non-small cell lung cancer (NCI-H522). All the compounds were tested in an <i>insilico</i> study, encompassing drug likeness and absorption, distribution, metabolism, and excretion (ADME) prediction. A molecular modelling simulation study of the promising compound <b>8a</b> in CDK-2 revealed the potential in vitro CDK-2 inhibitory assay result. The results demonstrate that, upon optimization, these novel indole-sulfonates could potentially act as new anticancer drugs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel indole-based scaffolds: Design, synthesis, molecular modeling, and anti-proliferative evaluation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Reham A. Mohamed-Ezzat,
  • Aisha A. K. Al-Ashmawy,
  • Aladdin M. Srour

摘要

Two novel series of indole-based scaffolds have been designed, synthesized, and screened for their anti-proliferative activities on the NCI-60 cell line panel. The novel structures of the indole-sulfonate and indole-aspirin mimic conjugates were designed as cyclin-dependent kinase 2 (CDK-2) inhibitors. The design approach depends on molecular hybridization between the indole scaffold and alkanesulfonates or with aspirin mimic analogs. The synthesized compounds were screened for their cytotoxic activity at a concentration of 10 µM. Compound 8a exhibited the most potent anticancer activity among the tested series and was further selected for the five-dose stage. At sub-micromolar doses, compound 8a showed anti-cancer potency against a panel of 60 tumor cell lines, with log GI50 values in the range from − 4.50 µM to -6.45 µM. With log GI50 values of -6.45, -6.42, -6.31, -5.96, and − 5.87 µM, respectively, the most sensitive cell lines were leukemia (SR), melanoma (MDA-MB-435), CNS cancer (SNB-75), ovarian cancer (OVCAR-3), and non-small cell lung cancer (NCI-H522). All the compounds were tested in an insilico study, encompassing drug likeness and absorption, distribution, metabolism, and excretion (ADME) prediction. A molecular modelling simulation study of the promising compound 8a in CDK-2 revealed the potential in vitro CDK-2 inhibitory assay result. The results demonstrate that, upon optimization, these novel indole-sulfonates could potentially act as new anticancer drugs.